Consistent Findings of Avelumab Maintenance for Metastatic Urothelial Carcinoma Shown in Real-World DataFebruary 20th 2023
In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.
Olverembatinib Induces Responses in Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALLDecember 13th 2022
An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Acute GVHD Responds Quickly to Itolizumab Treatment in Phase 1b TrialMay 3rd 2022
The positive results from EQUTE informed the doses that will be evaluated in the phase 3 EQUATOR trial of tolizumab versus placebo in combination with corticosteroids as a first-line treatment in patients with acute graft-versus-host disease.
Understanding irAEs Is Vital for IO Combo Use in HCCOctober 5th 2021
In an interview with during the 2021 International Liver Cancer Association Annual Conference, David J. Pinato, MD discussed combination strategies in hepatocellular carcinoma, how to manage associated toxicities, and how safety profiles can help to inform treatment decisions for this patient population.